Cannabics Pharmaceuticals Inc. (CNBX)

OTCMKTS: CNBX · Delayed Price · USD
0.0808
-0.0018 (-2.18%)
May 23, 2022 4:00 PM - Market closed
Market Cap100,616
Revenue (ttm)n/a
Net Income (ttm)-4.57M
Shares Out1.25M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume351,667
Open0.0752
Previous Close0.0826
Day's Range0.0750 - 0.0850
52-Week Range0.0750 - 25.3750
Beta1.57
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CNBX

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and ...

IndustryPharmaceuticals
Founded2004
CEOEyal Barad
Employees10
Stock ExchangeOTCMKTS
Ticker SymbolCNBX
Full Company Profile

News

CNBX Pharmaceuticals Granted Patent in Hong Kong

TEL AVIV, Israel and BETHESDA, Md. , May 5, 2022  /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, today announce...

2 weeks ago - PRNewsWire

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals

TEL AVIV, Israel and BETHESDA, Md. , March 28, 2022 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announ...

1 month ago - PRNewsWire

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

TEL AVIV, Israel and BETHESDA, Md., Nov. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

6 months ago - PRNewsWire

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago

TEL AVIV, Israel and BETHESDA, Md., Oct. 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

6 months ago - PRNewsWire

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Oct. 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

6 months ago - PRNewsWire

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

7 months ago - PRNewsWire

CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas

TEL AVIV, Israel and BETHESDA, Md., Oct. 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

7 months ago - PRNewsWire

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

7 months ago - PRNewsWire

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications ...

7 months ago - Benzinga

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

7 months ago - PRNewsWire

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pio...

7 months ago - PRNewsWire

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit...

TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

8 months ago - PRNewsWire

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Heal...

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

8 months ago - PRNewsWire

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pio...

8 months ago - PRNewsWire

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Aug. 23, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

9 months ago - PRNewsWire

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, annou...

9 months ago - PRNewsWire

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, anno...

10 months ago - PRNewsWire

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

10 months ago - PRNewsWire

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

TEL AVIV, Israel and BETHESDA, Md., June 28, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released ...

10 months ago - PRNewsWire

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Heal...

TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, anno...

11 months ago - PRNewsWire

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

TEL AVIV, Israel and BETHESDA, Md., June 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

11 months ago - PRNewsWire

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery...

TEL AVIV, Israel and BETHESDA, Md., May 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

11 months ago - PRNewsWire

Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations

TEL AVIV, Israel and BETHESDA, Md., May 11, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)

TEL AVIV, Israel and BETHESDA, Md., May 6, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Appr...

TEL AVIV, Israel and BETHESDA, Maryland, April 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, ann...

1 year ago - PRNewsWire